Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026

    Total solar eclipse crosses Russian Arctic and Europe

    August 13, 2026

    International Youth Day 2026 puts youth inclusion in focus

    August 13, 2026
    Facebook X (Twitter) Instagram
    haifajournal.comhaifajournal.com
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    haifajournal.comhaifajournal.com
    Home » MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
    PR Newswire

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    February 14, 2025
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email

    Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

    SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world’s first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    Revolutionizing Collagen Filler Technology

    SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body’s natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

    Why Recombinant Human Collagen?

    Highly Body-Friendly: SKINCOLLA’s recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

    With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

    Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

    Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it’s suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

    Cutting-Edge Technology for Long-Lasting Results

    The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

    Who Can Benefit from SKINCOLLA?

    SKINCOLLA is ideal for individuals seeking:

    Natural, subtle results without the “overdone” look often associated with traditional fillers.

    Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

    Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

    Indications for SKINCOLLA

    Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow’s feet, and marionette lines.

    Eyes: Dark circle reduction, eye wrinkles, and puffiness.

    Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

    For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact sales@maypharm.co.kr.

    Photo – https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/maypharm-co-ltd-launches-skincolla-the-worlds-first-recombinant-human-collagen-filler-for-superior-skin-rejuvenation-302376946.html


    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    Related Posts

    Nitinotes Announces Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center Clinical Site Activation in the EASE™ IDE Trial

    August 11, 2026

    Neurolief Expands Veterans’ Access to Prescription Neuromodulation for Depression and Migraine Through New VA Contract

    August 11, 2026

    WEKA and Andromeda Partner to Power AI Workloads at Global Scale

    July 30, 2026

    Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors

    July 30, 2026
    Latest News

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026

    Total solar eclipse crosses Russian Arctic and Europe

    August 13, 2026

    International Youth Day 2026 puts youth inclusion in focus

    August 13, 2026

    Etihad sets December start for Abu Dhabi Gothenburg flights

    August 13, 2026

    Diesel prices rise as US and Europe fuel supplies tighten

    August 12, 2026

    Meta, TikTok lose appeal as youth addiction cases proceed

    August 12, 2026

    Japan H3 rocket deploys Michibiki No. 7 into planned orbit

    August 12, 2026

    Europe heatwave puts EU economic growth under pressure

    August 11, 2026
    © 2026 Haifa Journal | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.